Journal article

The International ADHD in Substance Use Disorders Prevalence (IASP) study: background, methods and study population

Geurt Van De Glind, Katelijne Van Emmerik-Van Oortmerssen, Pieter Jan Carpentier, Frances R Levin, Maarten WJ Koeter, Csaba Barta, Sharlene Kaye, Arvid Skutle, Johan Franck, Maija Konstenius, Eli-Torild Bu, Franz Moggi, Geert Dom, Zolt Demetrovics, Melina Fatseas, Arild Schillinger, Mate Kapitany-Foeveny, Sofie Verspreet, Andrea Seitz, Brian Johnson Show all



Attention deficit/hyperactivity disorder (ADHD) is an increasingly recognized comorbid condition in subjects with substance use disorders (SUDs). This paper describes the methods and study population of the International ADHD in Substance Use Disorders Prevalence (IASP) study. Objectives of the IASP are to determine the prevalence of ADHD in adult treatment seeking patients with SUD in different countries and SUD populations, determine the reliability and validity of the Adult ADHD Self-report Scale V 1.1 (ASRS) as ADHD screening instrument in SUD populations, investigate the comorbidity profile of SUD patients with and without ADHD, compare risk factors and protective factors in SUD patient..

View full abstract


Awarded by Plan Nacional sobre Drogas, Ministerio de Sanidad y Politica Social

Awarded by Swiss Foundation of Alcohol Research

Awarded by European Social Fund


Funding Acknowledgements

In the period of development of the study the ICASA Network received unrestricted grants from the following pharmaceutical companies: Janssen Cilag, Eli Lilly & Company, Shire. Since the ICASA Network is a formal foundation (September 2010) it operates independent from pharmaceutical funding. Thus funding was obtained via the following sources:- Participating institutes;- The Noaber Foundation, The Waterloo Foundation, The Augeo Foundation. The local institutes report the following funding sources:- The Netherlands, Amsterdam: no external funding was obtained. The participating institute, Arkin, paid for the costs involved.- Norway, Bergen Clinics Foundation: Main external funding has been the Regional research council for addiction in West Norway (Regionalt kompetansesenter for rusmiddelforskning i Helse Vest (KORFOR)), funding a 50% position. The remaining resources, with staff and infrastructure, has been from the Bergen Clinics Foundation.- Norway, Fredrikstad: The IASP was funded by the hospital, Sykehuset Ostfold HF, not with money, but with 50% of the salary of the participants, then by two sources outside the hospital: The Regional centre of Dual Diagnosis and the social - and Health directory.- Sweden, Stockholm: The study was funded by the Stockholm Centre for Dependency Disorders.- Belgium: Funding of the IASP- project in Belgium: private funding.- France, Bordeaux: Research Grant PHRC (2006-2012) from the French Ministry of Health to M. Auriacombe and by a French National Research Agency PRA-CNRS-CHU-Bordeaux award (2008-2010) to M. Fatseas.- Spain, Barcelona: Financial support was received from Plan Nacional sobre Drogas, Ministerio de Sanidad y Politica Social (PND 0080/2011), the Agencia de Salut Publica de Barcelona and the Departament de Salut, Government of Catalonia, Spain- Switzerland, Berne/Zurich: The IASP in Switzerland was funded by the Swiss Foundation of Alcohol Research (Grant # 209).- Hungary, Budapest: There was no direct funding, but the following grant was used: The European Union and the European Social Fund have provided financial support to the project under the grant agreement no. TAMOP 4.2.1./B-09/1/KMR-2010-0003.- Australia: The IASP Screening Phase was funded by a strategic funding faculty grant from the Curtin University of Technology, Perth, Western Australia.- USA, Syracuse: no funding was obtained.